Similar articles for PMID: 24305454

Year	Number of Results
2000	2
2001	2
2002	4
2003	2
2004	1
2005	4
2006	4
2007	3
2008	2
2009	5
2010	8
2011	3
2012	6
2013	6
2014	5
2015	7
2016	4
2017	1
2018	11
2019	9
2020	8
2021	6
2022	4
2024	1

1

The new frontier of genetically targeted therapies for muscle disease.

Kang PB. Kang PB. Continuum (Minneap Minn). 2013 Dec;19(6 Muscle Disease):1698-702. doi: 10.1212/01.CON.0000440666.79792.84. Continuum (Minneap Minn). 2013. PMID: 24305454 Free PMC article.

2

Ethical Challenges in Early-Phase Pediatric Research for Life-Limiting Illness.

Unguru Y. Unguru Y. Semin Pediatr Neurol. 2015 Sep;22(3):177-86. doi: 10.1016/j.spen.2015.05.002. Epub 2015 May 12. Semin Pediatr Neurol. 2015. PMID: 26358428 Review.

3

Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy.

Kole R, Leppert BJ. Kole R, et al. Discov Med. 2012 Jul;14(74):59-69. Discov Med. 2012. PMID: 22846203 Free article. Review.

4

Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.

Peay HL, Biesecker BB, Wilfond BS, Jarecki J, Umstead KL, Escolar DM, Tibben A. Peay HL, et al. Clin Trials. 2018 Apr;15(2):139-148. doi: 10.1177/1740774517751118. Epub 2018 Feb 23. Clin Trials. 2018. PMID: 29475375 Free PMC article.

5

A genetically augmented future.

Clayton EW. Clayton EW. Nature. 2018 Dec;564(7735):S9. doi: 10.1038/d41586-018-07642-0. Nature. 2018. PMID: 30542180 No abstract available.

6

Risks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy.

Bos W, Westra AE, Pinxten W, Mayer MP, Lantos JD. Bos W, et al. Pediatrics. 2015 Dec;136(6):1173-7. doi: 10.1542/peds.2015-1589. Epub 2015 Nov 9. Pediatrics. 2015. PMID: 26553189 Free PMC article.

7

Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.

Guiraud S, Chen H, Burns DT, Davies KE. Guiraud S, et al. Exp Physiol. 2015 Dec;100(12):1458-67. doi: 10.1113/EP085308. Epub 2015 Aug 4. Exp Physiol. 2015. PMID: 26140505 Free PMC article. Review.

8

[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].

Zhang C, Feng HY, Huang SL, Fang JP, Xiao LL, Yao XL, Chen C, Ye X, Zeng Y, Lu XL, Wen JM, Zhang WX, Li Z, Feng SW, Xu HG, Huang K, Zhou DH, Chen W, Xie YM, Xi J, Zhang M, Li Y, Liu Y. Zhang C, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Aug;22(4):399-405. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005. PMID: 16086277 Chinese.

9

Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy.

Leigh F, Ferlini A, Biggar D, Bushby K, Finkel R, Morgenroth LP, Wagner KR. Leigh F, et al. Pediatrics. 2018 Oct;142(Suppl 2):S5-S16. doi: 10.1542/peds.2018-0333C. Pediatrics. 2018. PMID: 30275245

10

Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.

Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, Martin AS, Morris C, Rensch C, Ricotti V, Russo LJ, Sadosky A, Smith EC, Peay HL. Paquin RS, et al. Orphanet J Rare Dis. 2019 May 9;14(1):102. doi: 10.1186/s13023-019-1069-6. Orphanet J Rare Dis. 2019. PMID: 31072340 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year